THE WOODLANDS, Texas,
April 28, 2017 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release
its first quarter 2017 financial results on Tuesday, May 2, 2017 after market close.
Management will conduct a conference call and live webcast at
6:00 pm EDT (5:00 pm CT) that day to discuss the financial
results and to provide a corporate update.
Dial-in Information
U.S. Dial-in Number: (888)
645-5785
International Dial-in Number: (970) 300-1531
Conference ID: 8318299
Replay Information
U.S. Dial-in Number: (855)
859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 8318299
The dial-in replay will be available for 7 days following the
call. An audio webcast will be available online in the investor
relations section of the company website at
www.lexpharma.com/investors, with a webcast replay accessible for
14 days after the call.
About Lexicon
Lexicon is a fully integrated biopharmaceutical company that is
applying a unique approach to gene science based on Nobel
Prize-winning technology to discover and develop precise medicines
for patients with serious, chronic conditions. Through its
Genome5000™ program, Lexicon scientists have studied the role and
function of nearly 5,000 genes over the last 20 years and have
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to XERMELO, Lexicon has a pipeline of
promising drug candidates in clinical and pre-clinical development
in diabetes and metabolism and neuropathic pain. For additional
information please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's commercialization of
XERMELO (telotristat ethyl) 250 mg and clinical development of
sotagliflozin. In addition, this press release also contains
forward looking statements relating to Lexicon's growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All
forward‑looking statements are based on management's
current assumptions and expectations and involve risks,
uncertainties and other important factors, specifically including
the degree of market acceptance of XERMELO, the availability of
coverage and reimbursement for XERMELO, Lexicon's dependence on
third parties for manufacturing and distribution of XERMELO,
Lexicon's compliance with applicable legal and regulatory
requirements and other factors relating to the commercialization of
XERMELO. Other risks include Lexicon's ability to meet its capital
requirements, successfully conduct preclinical and clinical
development and obtain necessary regulatory approvals of
sotagliflozin and its other potential drug candidates, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates. Any of these risks, uncertainties and other factors may
cause Lexicon's actual results to be materially different from any
future results expressed or implied by such
forward‑looking statements. Information
identifying such important factors is contained under "Risk
Factors" in Lexicon's annual report on Form 10-K for the year ended
December 31, 2016, as filed with the Securities and Exchange
Commission. Lexicon undertakes no obligation to update or
revise any such forward-looking statements, whether as a result of
new information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lexicon-pharmaceuticals-to-host-first-quarter-2017-financial-results-conference-call-and-webcast-on-may-2-2017-300448116.html
SOURCE Lexicon Pharmaceuticals, Inc.